



2022 Alzheimer's Association International Conference (AAIC) Annual Meeting (San Diego, USA and Virtual): Eisai Inc. Oral Presentations and Posters

Please see the Eisai Inc. oral presentations and posters presented at the 2022 AAIC Annual Meeting listed below.

E2511

1. Aceves P, Hall N, Cai C, et al. First-In-Human (FIH), Single- And Multiple-Ascending-Dose (SAD/MAD) Studies in Healthy Subjects of E2511, A Novel Tropomyosin Receptor Kinase A (TrkA) Positive Allosteric Modulator (PAM). Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
2. Tomioka T, Hiramatsu N, Moriyama Y, et al. E2511, A Novel Small Compound TRKA Biased Positive Allosteric Modulators, Reinnervates Cholinergic Neuron and Activates Cholinergic Functions in Non-Clinical Studies. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.

General Alzheimer's disease

1. Aguilar BJ, Li M, Wang Y, et al. Healthcare Resource Utilization Among Veterans with Alzheimer's Disease. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
2. Charil A, Devanarayan V, Murali L, et al. Baseline Regional TAU Distribution Predicts Fast Cognitive Decline in Subjects with Mild Cognitive Impairment. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
3. Devanarayan V, Charil A, Nelson T, et al. Development and Validation of AI Based Tools for Brain Amyloid β Detection Using MRI. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.

4. Devanarayan V, Dhadda S, Koyama A, et al. Derivation and Evaluation of Signatures Using Plasma β -Amyloid and pTAU-181 for Brain Amyloid- β Detection. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
5. Horie K. Comprehensive CSF TAU Profiling Identifies Soluble TAU Pathophysiological Stages in Dominantly Inherited Alzheimer Network (DIAN): Implications for the DIAN-TU TAU Next Generation Platform. Oral Presentation presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
6. Li M, Wang Y, Aguilar BJ, et al. Concordance and Discordance in Disease Severity Classification Between Clinician Judgments and Cognitive Testing Scores for Alzheimer's Disease in the United States Veterans Affairs Healthcare System. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
7. Monfared AAT, Irizarry M, Stern Y, et al. Understanding Stigma in Alzheimer's Disease Through Social Media Narratives. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
8. Saxena S, Devanarayan V, Ye Y, et al. Novel peptide driven global proteomics platform to identify unique peptide profiles linked to Alzheimer's disease. Oral Presentation presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
9. Sivakumaran S, Cullen N, Cui Z, et al. Critical Path for Alzheimer's Disease (CPAD): Accelerating Drug Development and Therapeutic Innovation through Precompetitive Data Sharing and Quantitative Analytics. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
10. Yamashita K, Miura M, Watanabe S, et al. Highly specific plasma β -amyloid assays on the fully automated platform predict brain β -amyloid pathology determined by a Centiloid threshold of amyloid PET. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.

Lecanemab (BAN2401)

1. Grill JD, Flournoy C, Molina-Henry DP, et al. Diversity in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Lecanemab and Elenbecestat Early Alzheimer's Disease Studies. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
2. Hayato S, Rawal S, Takenaka O, et al. Subcutaneous Dose Selection of Lecanemab for Treatment of Subjects with Early Alzheimer's Disease. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
3. Honig LS, Sun Y, Irizarry MC, et al. Autopsy Findings in an Individual with Alzheimer's Disease who Received Long Term Treatment with Lecanemab (BAN2401). Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
4. Landry I, Kanekiyo M, Aluri J, et al. Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open Label Extension. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
5. Molina-Henry DP, Glover CM, Grill JD, et al. Strategies for diverse participant recruitment to a preclinical Alzheimer's disease trial: The AHEAD Study. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
6. Monfared AAT, Tafazzoli A, Ye W, et al. Lifetime Clinical Benefits of Lecanemab in Early Alzheimer's Disease Using Simulation Modeling. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual
7. Rawal S, Duong A, Landry I, et al. Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual
8. Reyderman L, Hayato S, Reddy H, et al. Modeled Impact of APOE4 Genotype on ARIA E Incidence in Patients Treated with Lecanemab. Oral Presentation presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual.
9. Yamauchi E, Kimura A, Hagiwara K, et al. Analysis of interaction characteristics between amyloid β and lecanemab by HDX-MS. Poster presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting; July 31 – Aug. 4, 2022; San Diego, USA and Virtual

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the oral presentations or poster(s) listed above, please submit your request via the medical information inquiry form available on our medical information website at www.eisaimedicalinformation.com/neurology/medicalinquiry or the Submit a Medical Inquiry Form available on our Medical Information website.

Please include specific details: Product(s), Oral Presentation/Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_medinfo@eisai.com or call 1-888-274-2378.